Monopar Therapeutics has spent two years turning a discarded Wilson disease asset into a live Food and Drug Administration review. In late July the company started a rolling new-drug application for ALXN1840, the once-daily copper binder that Alexion, the rare-disease unit of AstraZeneca, abandoned after mechanistic studies disappointed regulators. The equity is no longer a radiopharma micro-cap story. It is a single-asset regulatory claim on whether a pivotal copper-mobilization win, plus newer neurologic re-analyses, can succeed where a large rare-disease owner declined to file.
The tension is that the same data package already failed a prior owner's conversations with regulators. Alexion ended the program after two mechanistic studies missed their endpoints, even though the larger FoCus trial had met its primary copper measure. Monopar's wager is that those misses were methodological and that neurologic and copper-balance work presented through mid-year is enough to carry a filing. Cash and investments of $134 million at the June quarter-end are guided to cover operations through year-end twenty twenty-seven, including a commercial build that is already lifting contractor spend.
The next several quarters resolve a narrow question. Does the agency accept the completed rolling package for review, and does the eventual decision treat copper mobilization plus neurologic benefit as an approvability story rather than a reason to demand another controlled trial?